

Erratum to: Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions

Naveen S. Vasudev · Andrew R. Reynolds

Published online: 4 June 2014
© Springer Science+Business Media Dordrecht 2014

Erratum to: Angiogenesis DOI 10.1007/s10456-014-9420-y

The author wishes to correct the errors in Table 1 of the original publication.

The content in Table 1, under the section entitled ‘Colorectal cancer’ has three errors.

1. For the AVF2107 trial, in the treatment column, “FOLFIRI” should be replaced with “IFL”

2. For the NO16966 trial, in the outcome column “Improvement in OS and PFS” should be replaced with “Improvement in PFS” and
3. Definitions of the abbreviations IFL and XELOX were omitted and have been added to the foot of the table.

The correct Table 1 is provided in this Erratum.

The online version of the original article can be found under doi:[10.1007/s10456-014-9420-y](https://doi.org/10.1007/s10456-014-9420-y).

N. S. Vasudev · A. R. Reynolds (✉)
Tumour Biology Team, Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
e-mail: andrew.reynolds@icr.ac.uk

Present Address:

N. S. Vasudev
Cancer Research UK Centre, Leeds Institute of Cancer and Pathology, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK

Table 1 Randomised trials of anti-angiogenic agents cited in this article

Indication	Treatment	Trial identifier and citation	Outcome
<i>Breast cancer</i>			
Metastatic 1st line	Paclitaxel ± bevacizumab	E2100 [40]	Improvement in PFS not OS
	Docetaxel ± bevacizumab (HER-2 negative population)	AVADO [41]	Improvement in PFS, OS NA
	Capecitabine, taxane or anthracycline ± bevacizumab (HER-2 negative population)	RIBBON-1 [42]	Improvement in PFS but not in OS
	Docetaxel and trastuzumab ± bevacizumab (HER-2 positive population)	AVEREL [104]	No improvement in PFS, OS NA
	Docetaxel ± sunitinib (HER-2 negative population)	Sun 1064 [45]	No improvement in PFS or OS
	Paclitaxel ± bevacizumab or sunitinib (HER-2 negative population)	SUN 1094 [46]	Inferior PFS for sunitinib arm
Metastatic 2nd line and beyond	Capecitabine ± bevacizumab	AVF2119 [39]	No improvement in PFS or OS
	Capecitabine, taxane, gemcitabine, or vinorelbine ± bevacizumab (HER-2 negative population)	RIBBON-2 [43]	Improvement in PFS but not in OS
	Capecitabine ± sunitinib	NCT00435409 [44]	No improvement in PFS or OS
Adjuvant	Capecitabine vs. sunitinib (HER-2 negative population)	SUN 1107 [47]	Inferior PFS and OS for sunitinib arm
	Anthracycline, taxane or both ± bevacizumab (triple negative population)	BEATRICE [58]	No improvement in DFS, OS NA
Neo-adjuvant	Doxorubicin/docetaxel/cyclophosphamide ± bevacizumab	NCT00408408 [63]	Improvement in pathological complete response rate (primary endpoint)
	Epirubicin/docetaxel/Cyclophosphamide ± bevacizumab (HER-2 negative population)	NCT00567554 [64]	Improvement in pathological complete response rate (primary endpoint)
<i>Colorectal cancer</i>			
Metastatic 1st line	IFL ± bevacizumab	AVF2107 [19]	Improvement in OS and PFS
	FOLFOX or XELOX ± bevacizumab	NO16966 [21]	Improvement in PFS
	Capecitabine ± bevacizumab	AVEX [22]	Improvement in PFS, OS NA
	FOLFIRI ± sunitinib	SUN1122 [28]	No improvement in PFS
	FOLFOX ± vatalanib	CONFIRM 1 [29]	No improvement in PFS or OS
Metastatic 2nd line and beyond	FOLFOX ± bevacizumab	E3200 [20]	Improvement in OS and PFS
	FOLFOX ± vatalanib	CONFIRM 2 [30]	Improvement in PFS but not OS
	FOLFIRI ± aflibercept	VELOUR [27]	Improvement in OS and PFS
	Regorafenib versus placebo	CORRECT [31]	Improvement in OS
Continuation beyond progression	Chemotherapy ± bevacizumab	ML18 147 [92]	Improvement in OS
Adjuvant	FOLFOX ± bevacizumab	NSABP C-08 [56]	No improvement in OS
	FOLFOX or XELOX ± bevacizumab	AVANT [57]	No improvement in OS
<i>Hepatocellular carcinoma</i>			
Metastatic 1st line	Sorafenib versus placebo	NCT00105443 [17]	Improvement in PFS and OS
	Brivanib versus sorafenib	BRISK-FL [145]	OS non-inferiority end-point for brivanib versus sorafenib not met
Metastatic 2nd line	Brivanib versus placebo	BRISK-PS [146]	Improvement in PFS but not OS

Table 1 continued

Indication	Treatment	Trial identifier and citation	Outcome
<i>Melanoma</i>			
Metastatic 1st line	Paclitaxel/carboplatin ± bevacizumab	BEAM*** [48]	No improvement in PFS or OS
	Paclitaxel/carboplatin ± sorafenib	NCT00110019 [49]	No improvement in PFS or OS
Metastatic 2nd line	Paclitaxel/carboplatin ± sorafenib	NCT00111007 [50]	No improvement in PFS or OS
<i>NSCLC*</i>			
Metastatic 1st line	Paclitaxel/carboplatin ± bevacizumab	NCT00021060 [32]	Improvement in PFS and OS
	Cisplatin/gemcitabine ± bevacizumab	AVAiL [33]	Improvement in PFS but not OS
<i>Ovarian cancer</i>			
Metastatic 1st line	Paclitaxel/carboplatin ± bevacizumab	ICON-7 [36]	Improvement in PFS, OS NA
	Paclitaxel/carboplatin ± bevacizumab	GOG218 [37]	Improvement in PFS, OS confounded by cross-over
Metastatic 2nd line	Gemcitabine/carboplatin ± bevacizumab	OCEANS [38]	Improvement in PFS but not OS
<i>Pancreatic cancer</i>			
Metastatic 1st line	Gemcitabine ± bevacizumab	CALGB 80303 [51]	No improvement in PFS or OS
<i>PNET</i>			
Metastatic 1st line	Sunitinib versus placebo	NCT00428597 [18]	Improvement in PFS, OS NA
<i>Prostate cancer**</i>			
Metastatic 1st line	Docetaxel/prednisone ± bevacizumab	CALGB 90401 [52]	Improvement in PFS but not OS
	Docetaxel/prednisone ± aflibercept	VENICE [53]	No improvement in PFS or OS
<i>Renal cancer</i>			
Metastatic 1st line	Sorafenib versus placebo	TARGET [9]	Improvement in PFS and OS
	Sunitinib versus interferon-alpha	NCT00098657 [11]	Improvement in PFS and OS
	Pazopanib versus placebo	NCT00334282 [13]	Improvement in PFS, OS confounded by cross-over
Metastatic 2nd line	Sunitinib versus pazopanib	COMPARZ [15]	PFS and OS were similar
	Axitinib versus sorafenib	AXIS [16]	Improvement in favour of axitinib for PFS but not OS

DFS disease-free survival, *FOLFIRI* 5-FU, leucovorin and irinotecan, *FOLFOX* 5-FU, leucovorin and oxaliplatin, *HER-2* human epidermal growth factor receptor-2, *IFL* irinotecan, 5FU and leucovorin, *NA* not available (pending, unknown or not reported), *NSCLC* non-small cell lung cancer, *OS* overall survival, *PNET* pancreatic neuroendocrine tumour, *PFS* progression-free survival, *XELOX* capecitabine and oxaliplatin

* Non-squamous NSCLC only; ** castration resistant; *** randomised phase II study